|Bid||206.09 x 1100|
|Ask||206.05 x 900|
|Day's range||203.13 - 207.36|
|52-week range||187.16 - 468.55|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||21.10|
|Earnings date||20 Jul 2022 - 25 Jul 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||241.96|
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
With its shares down by more than 22% in the last 12 months, it's clear that Biogen (NASDAQ: BIIB) isn't the high-flying growth stock that it used to be. Since its failed attempt over the last year to get its fiercely criticized Alzheimer's disease drug Aduhelm approved for sale, the company's troubles have turned from bad to worse. Revenue and earnings from its core drug products are both down sharply over the last three years.